OCREVID Study (The management of OCRElizumab during the coVID-19 pandemic in Italy)
---
Privacy Policy
Fondazione Italiana Sclerosi Multipla – FISM – Ente del Terzo Settore/ETS e, in forma abbreviata, FISM ETS.Iscrizione al RUNTS Rep. N° 89695 - Fondazione con Riconoscimento di Personalità Giuridica - C.F. 95051730109
Copyright © 2025 - All Rights Reserved - Italian Multiple Sclerosis Register
Website Italian Multiple Sclerosis Register & OS Templates
OCREVID Study (The management of OCRElizumab during the coVID-19 pandemic in Italy)
---
---
---